Advertisement
The presentations include a 36-month update of a multi-center study thatdemonstrates the safety, effectiveness and durability of cryoablation as ameans of dramatically reducing focal pain for patients whose cancer has spreadto their bones. The update on the study, which includes data from 50 of aplanned total of 60 patients, is being presented by Matthew Callstrom, M.D.,PhD of Mayo Clinic, the lead investigator.
Advertisement
The conference also includes several presentations focused on percutaneousrenal, or kidney, cryoablation, the fastest growing cryoablation treatment.Last January the Centers for Medicare and Medicaid Services issued for thefirst time a payment code for percutaneous renal cryoablation, a procedurethat allows physicians to destroy small tumors in the kidney by inserting aprobe directly through the skin and freezing the cancerous tissue.
Data were also presented on the effectiveness of cryoablation for treatingliver, lung and brain cancers, as well as an immunologic response that occursin high risk prostate cancer patients treated with cryoablation.
"We are very excited that so many of the world's leading and most creativeinterventional radiologists are looking to cryoablation as a treatment forbone pain, lung and kidney cancers, in addition to the more traditional use ofcryoablation to treat prostate cancer," said Endocare interim CEO Terrence A.Noonan. "The promising RSNA data and the enthusiasm cryoablation is generatingamong physicians supports our contention that cryoablation is a platformmedical technology that can be beneficial to patients with a wide variety ofcancers. From a strictly business standpoint, cryoablation for prostate cancerremains a core focus, but this conference demonstrates that there is a broadfuture for cryoablation as a safe and effective treatment for many forms ofcancer."
About Endocare
Endocare, Inc. -- www.endocare.com -- is an innovative medical devicecompany focused on the development of minimally invasive technologies fortissue and tumor ablation. Endocare has initially concentrated on developingtechnologies for the treatment of prostate cancer and believes that itsproprietary technologies have broad applications across a number of markets,including the ablation of tumors in the kidney, lung and liver and palliativeintervention (treatment of pain associated with metastases).
Statements in this press release that are not historical facts areforward-looking statements that involve risks and uncertainties. Among theimportant factors that could cause actual results to differ materially fromthose in the forward-looking statements include, but are not limited to, thosediscussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q and otherfilings with the Securities and Exchange Commission. Such risk factorsinclude, but are not limited to, the following items: the Company has alimited operating history with significant losses and losses may continue inthe future; the Company may require additional financing to sustain itsoperations and without it the Company may not be able to continue operations;the Company's business may be materially and adversely impacted by the loss ofthe Company's largest customer or the reduction, delay or cancellation oforders from this customer or if this customer delays payment or fails to makepayment; the Company may be required to make state and local tax payments thatexceed the Company's settlement estimates; uncertainty regarding the abilityto convince health care professionals and third party payers of the medicaland economic benefits of the Company's products; uncertainty relating to thirdparty reimbursement; the risk that intense competition and rapid technologicaland industry change may make it more difficult for the Company to achievesignificant market penetration; and uncertainty regarding the ability tosecure and protect intellectual property rights relating to the Company'stechnology. The actual results that the Company achieves may differ materiallyfrom any forward-looking statements due to such risks and uncertainties. TheCompany undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.Investors, Matt Clawson Allen & Caron, Inc. (949) 474-4300 [email protected] www.allencaron.com Media Contact: Len Hall Allen & Caron, Inc. (949) 474-4300 [email protected] www.allencaron.com For Additional Information: Terrence A. Noonan, CEO Michael R. Rodriguez, CFO Endocare, Inc. (949) 450-5400 www.endocare.com
SOURCE Endocare, Inc.
